1. Figure 4 Example of a patients with CUP
who received EPICUP-predicted matching site-specific treatment
Figure 4 | Example of a patients with CUP who received EPICUP-predicted matching site-specific treatment. In this patient with CUP, for whom epigenetic profiling using EPICUP predicted a non-small-cell lung cancer (NSCLC) primary, a diagnosis validated by haematoxylin and eosin (H&E) staining; immunohistochemistry for the cytokeratins CK-7 (positive) and CK-20 (negative), and the specific lung marker homeobox protein Nkx-2.1 (TTF-1; positive); and real-time PCR specific for the G719X mutation in EGFR (positive), black lines: negative controls. This patient subsequently received treatment with the EGFR inhibitor erlotinib.
Moran, S. et al. (2017) Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
Nat. Rev. Clin. Oncol. doi: /nrclinonc